Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Apr 20;64(12):1765–1768. doi: 10.1136/ard.2005.036459

Do steroids increase lymphoma risk? A case–control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis

J Askling 1, L Klareskog 1, H Hjalgrim 1, E Baecklund 1, M Bjorkholm 1, A Ekbom 1
PMCID: PMC1755302  PMID: 15843445

Abstract

Background: Recent studies indicate increased risks of malignant lymphomas among individuals treated with corticosteroids, but have not taken into account the underlying reasons for steroid use, so the increased risks might be attributable to the underlying disease or concomitant treatments other than steroids. Polymyalgia rheumatica (PMR) and temporal arteritis (giant cell arteritis, GCA) are common inflammatory conditions treated with steroids as single immunosuppressive therapy, but data on lymphoma risk in GCA/PMR are limited.

Objective: To assess the risk of lymphoma associated with steroid treatment of GCA/PMR.

Methods: The association between GCA/PMR and malignant lymphomas (overall, and separately for non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphatic leukaemia) was examined in a nationwide, population based, case–control study of 42 676 lymphoma cases and 78 487 matched population controls, using prospectively recorded data on lymphomas from the Swedish cancer register 1964–2000 and data on pre-lymphoma hospital admissions for GCA/PMR from the Swedish inpatient register 1964–2000. Odds ratios (OR) associated with a pre-lymphoma hospital admission for GCA/PMR were calculated using conditional logistic regression.

Results: 153 lymphoma cases and 345 population controls had a history of GCA/PMR, resulting in an overall OR for malignant lymphomas of 0.81 (95% confidence interval, 0.67 to 0.98). The OR varied little with lymphoma type, sex, age, and calendar period. The OR for GCA was 0.67 (0.48 to 0.98) and for PMR, 0.83 (0.67 to 1.04).

Conclusions: Treated GCA is not associated with increased lymphoma risks, which suggests that even at considerable cumulative doses, steroids may not appreciably increase lymphoma risk.

Full Text

The Full Text of this article is available as a PDF (71.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asten P., Barrett J., Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999 Aug;26(8):1705–1714. [PubMed] [Google Scholar]
  2. Baecklund E., Ekbom A., Sparén P., Feltelius N., Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998 Jul 18;317(7152):180–181. doi: 10.1136/bmj.317.7152.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Behn A. R., Perera T., Myles A. B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis. 1983 Aug;42(4):374–378. doi: 10.1136/ard.42.4.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beiderbeck Annette B., Holly Elizabeth A., Sturkenboom Miriam C. J. M., Coebergh Jan W., Stricker Bruno H. Ch, Leufkens Hubert G. M. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control. 2003 Sep;14(7):639–644. doi: 10.1023/a:1025698109991. [DOI] [PubMed] [Google Scholar]
  5. Birkeland S. A., Storm H. H., Lamm L. U., Barlow L., Blohmé I., Forsberg B., Eklund B., Fjeldborg O., Friedberg M., Frödin L. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995 Jan 17;60(2):183–189. doi: 10.1002/ijc.2910600209. [DOI] [PubMed] [Google Scholar]
  6. Björnådal Lena, Baecklund Eva, Yin Li, Granath Fredrik, Klareskog Lars, Ekbom Anders. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol. 2002 May;29(5):906–912. [PubMed] [Google Scholar]
  7. Björnådal Lena, Löfström Björn, Yin Li, Lundberg Ingrid E., Ekbom Anders. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002;31(2):66–71. doi: 10.1080/03009740252937568. [DOI] [PubMed] [Google Scholar]
  8. Cartwright R. A., McKinney P. A., O'Brien C., Richards I. D., Roberts B., Lauder I., Darwin C. M., Bernard S. M., Bird C. C. Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leuk Res. 1988;12(1):81–88. doi: 10.1016/s0145-2126(98)80012-x. [DOI] [PubMed] [Google Scholar]
  9. Cerhan James R., Anderson Kristin E., Janney Carol A., Vachon Celine M., Witzig Thomas E., Habermann Thomas M. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer. 2003 Sep 20;106(5):784–788. doi: 10.1002/ijc.11311. [DOI] [PubMed] [Google Scholar]
  10. Chuang T. Y., Hunder G. G., Ilstrup D. M., Kurland L. T. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982 Nov;97(5):672–680. doi: 10.7326/0003-4819-97-5-672. [DOI] [PubMed] [Google Scholar]
  11. Duhaut P., Bosshard S., Dumontet C. Giant cell arteritis and polymyalgia rheumatica: role of viral infections. Clin Exp Rheumatol. 2000 Jul-Aug;18(4 Suppl 20):S22–S23. [PubMed] [Google Scholar]
  12. Ekström Karin, Hjalgrim Henrik, Brandt Lena, Baecklund Eva, Klareskog Lars, Ekbom Anders, Askling Johan. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003 Apr;48(4):963–970. doi: 10.1002/art.10939. [DOI] [PubMed] [Google Scholar]
  13. Haga H. J., Eide G. E., Brun J., Johansen A., Langmark F. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993 Aug;20(8):1335–1339. [PubMed] [Google Scholar]
  14. Hazleman B. L. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis. 1982;41 (Suppl 1):12–17. doi: 10.1136/ard.41.suppl_1.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Herrick A. L., McColl K. E. Lack of certainty on the diagnosis of acute intermittent porphyria: comment on the concise communication by Cohen et al. Arthritis Rheum. 1998 Jan;41(1):188–189. doi: 10.1002/1529-0131(199801)41:1<188::AID-ART34>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  16. Holly Elizabeth A., Bracci Paige M. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol. 2003 Aug 15;158(4):316–327. doi: 10.1093/aje/kwg145. [DOI] [PubMed] [Google Scholar]
  17. Kamel O. W., Weiss L. M., van de Rijn M., Colby T. V., Kingma D. W., Jaffe E. S. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol. 1996 Oct;20(10):1279–1287. doi: 10.1097/00000478-199610000-00015. [DOI] [PubMed] [Google Scholar]
  18. Kato Ikuko, Koenig Karen L., Shore Roy E., Baptiste Mark S., Lillquist Patricia P., Frizzera Glauco, Burke Jerome S., Watanabe Hiroko. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control. 2002 Dec;13(10):965–974. doi: 10.1023/a:1021953224822. [DOI] [PubMed] [Google Scholar]
  19. Kinlen L. J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985 Jan 21;78(1A):44–49. doi: 10.1016/0002-9343(85)90245-1. [DOI] [PubMed] [Google Scholar]
  20. Knight Ann, Askling Johan, Ekbom Anders. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002 Jul 1;100(1):82–85. doi: 10.1002/ijc.10444. [DOI] [PubMed] [Google Scholar]
  21. Lunde A. S., Lundeborg S., Lettenstrom G. S., Thygesen L., Huebner J. The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 2. 1980;(84):1–59. [PubMed] [Google Scholar]
  22. Matteson E. L., Gold K. N., Bloch D. A., Hunder G. G. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med. 1996 Feb;100(2):193–196. doi: 10.1016/s0002-9343(97)89458-2. [DOI] [PubMed] [Google Scholar]
  23. Mattsson B., Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305–313. doi: 10.3109/02841868409136026. [DOI] [PubMed] [Google Scholar]
  24. Myklebust Geirmund, Wilsgaard Tom, Jacobsen Bjarne Koster, Gran Jan Tore. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002 Oct;29(10):2143–2147. [PubMed] [Google Scholar]
  25. Nuenninghoff D. M., Matteson E. L. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S29–S34. [PubMed] [Google Scholar]
  26. Petursdottir V., Johansson H., Nordborg E., Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) 1999 Dec;38(12):1208–1212. doi: 10.1093/rheumatology/38.12.1208. [DOI] [PubMed] [Google Scholar]
  27. Salvarani C., Gabriel S. E., O'Fallon W. M., Hunder G. G. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995 Aug 1;123(3):192–194. doi: 10.7326/0003-4819-123-3-199508010-00006. [DOI] [PubMed] [Google Scholar]
  28. Salvarani C., Macchioni P. L., Tartoni P. L., Rossi F., Baricchi R., Castri C., Chiaravalloti F., Portioli I. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol. 1987 Jul-Sep;5(3):205–215. [PubMed] [Google Scholar]
  29. Schaufelberger C., Bengtsson B. A., Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol. 1995 Mar;34(3):261–264. doi: 10.1093/rheumatology/34.3.261. [DOI] [PubMed] [Google Scholar]
  30. Sørensen Henrik Toft, Mellemkjaer Lene, Nielsen Gunnar Lauge, Baron John A., Olsen Jørgen H., Karagas Margaret R. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst. 2004 May 5;96(9):709–711. doi: 10.1093/jnci/djh118. [DOI] [PubMed] [Google Scholar]
  31. Weyand Cornelia M., Goronzy Jörg J. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003 Sep 16;139(6):505–515. doi: 10.7326/0003-4819-139-6-200309160-00015. [DOI] [PubMed] [Google Scholar]
  32. Zhang Yawei, Holford Theodore R., Leaderer Brian, Zahm Shelia Hoar, Boyle Peter, Morton Lindsay McOmber, Zhang Bing, Zou Kaiyong, Flynn Stuart, Tallini Giovanni. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control. 2004 May;15(4):419–428. doi: 10.1023/B:CACO.0000027506.55846.5d. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES